Hülya Günbatar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hülya Günbatar has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Emin Erbaycu
Department of Pulmonology, Cigli Training and Research Hospital, Izmir Bakırçay University, 35620 Izmir, Türkiye
1 shared publication - Ahmet Ufuk Kömüroğlu
Van Yuzuncu Yil University, Vocational School of Health Services, 65080, Van, Turkey
1 shared publication - Arife Ulas
Department of Medical Oncology, University of Health Sciences, Bursa City Education and Research Hospital, Bursa 16250, Türkiye
1 shared publication - Ayse Bahadir
Basaksehir Cam and Sakura City Hospital, Department of Pulmonology, Istanbul, Turkey
1 shared publication - Aysegul Senturk
Department of Chest Diseases, Ankara Atatürk Training and Research Hospital, Ankara, Turkey
1 shared publication - Aysel Sünnetçioğlu
Van Yuzuncu Yil Universitesi
1 shared publication
Latest Publications
- Open Access
- 30 August 2025
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- Vol. 18 (2) , 123-130
Lipolyse Enzyms Levels in Patients with Obstructive Sleep Apnea Syndrome; Especially Perilipin-1
Introduction: Since obesity is an important risk factor in obstructive sleep apnea syndrome (OSAS), it will be important to determine the relationship between intracellular and intravascular lipolysis enzymes and OSAS. In this study we investigated the levels of lipolysis enzymes Perilipin-1 (Plin-1), adipose triglyceride lipase (ATGL), hormon sensitive lipase (HSL) and lipoprotein lipase (LPL) in patients with OSAS and the relationship between these enzymes and OSAS. Material method: 51 OSAS patients with obstructive sleep apnea syndrome and 25 volunteers diagnosed with simple snoring as a control group were included in the study. Polysomnographic evaluation, age, gender, and body mass index of each participant were recorded. Blood was taken from the participants on the same day to analyze enzymes. Results: Between the OSAS group (n:51) and the control group (n:25), age (mean: 45.3±10 vs 40.9±9.1, p value: 0.065), gender (female/male in the patient and control group, respectively: 5/46, 3/22, p value: 0.76) and BMI (min-max 23.3-40.1 vs 24-44.1, p value: 0.21, respectively) were similar. For ATGL, HSL, LPL, no significant difference was detected between the groups (median values: 65.9 vs 68.3, 7.30 vs 7.33, 484.2 vs 485.3, p values: 0.33, 0.69, 0.33, respectively). Plin-1 level was found to be significantly higher in the OSAS group (median value: 5.34 vs 4.87 ng/ml, p:0.038). It was determined that Plin-1 had a positive correlation with WASO (wake after sleep onset) and a negative correlation with total sleep time (p value: 0.003, 0.006, r value: 0.41, -0.38, respectively). In the linear regression analysis performed for the OSAS group, WASO was detected as a risk factor for Plin-1 elevation (p: 0.003, B: 0.012). Conclusion: We found that Plin-1 levels increased secondary to sleep disruptions in patients with OSAS, independent of obesity.
- 30 August 2025
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- Vol. 18 (2) , 123-130
Open AccessLipolyse Enzyms Levels in Patients with Obstructive Sleep Apnea Syndrome; Especially Perilipin-1
Introduction: Since obesity is an important risk factor in obstructive sleep apnea syndrome (OSAS), it will be important to determine the relationship between intracellular and intravascular lipolysis enzymes and OSAS. In this study we investigated the levels of lipolysis enzymes Perilipin-1 (Plin-1), adipose triglyceride lipase (ATGL), hormon sensitive lipase (HSL) and lipoprotein lipase (LPL) in patients with OSAS and the relationship between these enzymes and OSAS. Material method: 51 OSAS patients with obstructive sleep apnea syndrome and 25 volunteers diagnosed with simple snoring as a control group were included in the study. Polysomnographic evaluation, age, gender, and body mass index of each participant were recorded. Blood was taken from the participants on the same day to analyze enzymes. Results: Between the OSAS group (n:51) and the control group (n:25), age (mean: 45.3±10 vs 40.9±9.1, p value: 0.065), gender (female/male in the patient and control group, respectively: 5/46, 3/22, p value: 0.76) and BMI (min-max 23.3-40.1 vs 24-44.1, p value: 0.21, respectively) were similar. For ATGL, HSL, LPL, no significant difference was detected between the groups (median values: 65.9 vs 68.3, 7.30 vs 7.33, 484.2 vs 485.3, p values: 0.33, 0.69, 0.33, respectively). Plin-1 level was found to be significantly higher in the OSAS group (median value: 5.34 vs 4.87 ng/ml, p:0.038). It was determined that Plin-1 had a positive correlation with WASO (wake after sleep onset) and a negative correlation with total sleep time (p value: 0.003, 0.006, r value: 0.41, -0.38, respectively). In the linear regression analysis performed for the OSAS group, WASO was detected as a risk factor for Plin-1 elevation (p: 0.003, B: 0.012). Conclusion: We found that Plin-1 levels increased secondary to sleep disruptions in patients with OSAS, independent of obesity.
- Open Access
- 9 March 2023
- Published by Ahi Evran Medical Journal, Kirsehir Ahi Evran University in Ahi Evran Medical Journal
- Vol. 7 (1) , 114-123
The Status of Antioxidants and Oxidative Damage in Patients with COVID-19
Purpose: COVID-19 is a viral disease that has recently caused a pandemic and significantly affects human health. In this study, superoxide dismutase, glutathione peroxidase, glutathione, total thiol, natural thiol, disulfide, oxidative DNA damage and malondialdehyde levels in COVID-19 were investigated. Materials and Methods: Thirty-five patients and 35 healthy volunteers were included in this study. The diagnosis of COVID-19 was made by reverse transcriptase-polymerase chain reaction. Serum glutathione, glutathione peroxidase, superoxide dismutase, natural thiol, total thiol and disulphide levels by enzyme-linked immunosorbent assay and malondialdehyde and 8-hydroxy-2-deoxyguanosine/10⁶ deoxyguanosine levels by high-pressure liquid chromatography measured. Results: While serum superoxide dismutase, glutathione peroxidase, malondialdehyde, 8-hydroxy-2-deoxyguanosine/10⁶ deoxyguanosine, disulfide levels were higher in the COVID-19 patient group than in the healthy control group, glutathione, total thiol, natural thiol levels were lower. In addition, there was a negative correlation between 8-hydroxy-2-deoxyguanosine/10⁶ deoxyguanosine and glutathione, natural thiol and total thiol, and a positive correlation with disulfide. Conclusion: This study revealed that serum superoxide dismutase, glutathione peroxidase, malondialdehyde, 8-hydroxy-2-deoxyguanosine/10⁶ deoxyguanosine, and disulfide levels increased and glutathione, thiol and natural thiol levels decreased in COVID-19 patients. These results revealed that there was a decrease in antioxidant marker levels and an increase in oxidative stress markers in COVID-19 patients.
- 9 March 2023
- Published by Ahi Evran Medical Journal, Kirsehir Ahi Evran University in Ahi Evran Medical Journal
- Vol. 7 (1) , 114-123
Open AccessThe Status of Antioxidants and Oxidative Damage in Patients with COVID-19
Purpose: COVID-19 is a viral disease that has recently caused a pandemic and significantly affects human health. In this study, superoxide dismutase, glutathione peroxidase, glutathione, total thiol, natural thiol, disulfide, oxidative DNA damage and malondialdehyde levels in COVID-19 were investigated. Materials and Methods: Thirty-five patients and 35 healthy volunteers were included in this study. The diagnosis of COVID-19 was made by reverse transcriptase-polymerase chain reaction. Serum glutathione, glutathione peroxidase, superoxide dismutase, natural thiol, total thiol and disulphide levels by enzyme-linked immunosorbent assay and malondialdehyde and 8-hydroxy-2-deoxyguanosine/10⁶ deoxyguanosine levels by high-pressure liquid chromatography measured. Results: While serum superoxide dismutase, glutathione peroxidase, malondialdehyde, 8-hydroxy-2-deoxyguanosine/10⁶ deoxyguanosine, disulfide levels were higher in the COVID-19 patient group than in the healthy control group, glutathione, total thiol, natural thiol levels were lower. In addition, there was a negative correlation between 8-hydroxy-2-deoxyguanosine/10⁶ deoxyguanosine and glutathione, natural thiol and total thiol, and a positive correlation with disulfide. Conclusion: This study revealed that serum superoxide dismutase, glutathione peroxidase, malondialdehyde, 8-hydroxy-2-deoxyguanosine/10⁶ deoxyguanosine, and disulfide levels increased and glutathione, thiol and natural thiol levels decreased in COVID-19 patients. These results revealed that there was a decrease in antioxidant marker levels and an increase in oxidative stress markers in COVID-19 patients.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , PA4311
General characteristics and therapeutic options in lung cancer in Turkey
ASPECT study, a prospective multicenter study conducted in Turkey with the participation of 26 centers, including all patients with lung cancer, who agreed to participate in the study, were re-evaluated in terms of demographic characteristics of patients (pts), disease characteristics, and the treatment options in lung cancer. Among 1245 cases (88.7% man) included, %83.4 had advanced stage (stage 3-4) lung cancer. Histopathologic types were squamous cell in 39.3%, adenocancer in 29.6%, SCLC in 19.0%, NSCLC in 10.2% and others. Of the pts, 45.5% had a comorbid disease, 49.3% had weight loss (at least 5% of body weight), and 31.6% had a history of cancer in family. PET-CT was used in 83.3% of the pts for diagnosis of staging. Metastasis was detected in 54.2% of pts (43.9% bone, 23.1% brain, %20.2% liver, 17.3% surrenal metastasis). Treatment options were chemotherapy in 45.9%, chemo-radiotherapy in 28.2%, and surgery in 18.4% of the pts. Chemotherapy was mostly platin based doubles including etoposide (14.9%), paclitaxel (14.0%), gemcitabine (12.3%), docetaxol (4.3%), pemetrexed (2.2%), vinorelbin (4.9%), and others. The use of targeted therapies was detected in 1.1% of the pts. Palliative radiotherapy was given in 21.1% of the pts (8.5% brain, 7.2% bone, 6.7% thorax, and others). Interventional bronchoscopy or bronchial stenting was performed in 2.0% and pleurodesis in 1.8%. Of the pts, 10.5% reported the use of herbal medicine products. Most pts with lung cancer presented in advanced stages and only 18.4% had a chance for surgery. Conventional chemotherapy and radiotherapy was the most common therapeutic options but the use of targeted therapies and interventional procedures seems to be quite low.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , PA4311
General characteristics and therapeutic options in lung cancer in Turkey
ASPECT study, a prospective multicenter study conducted in Turkey with the participation of 26 centers, including all patients with lung cancer, who agreed to participate in the study, were re-evaluated in terms of demographic characteristics of patients (pts), disease characteristics, and the treatment options in lung cancer. Among 1245 cases (88.7% man) included, %83.4 had advanced stage (stage 3-4) lung cancer. Histopathologic types were squamous cell in 39.3%, adenocancer in 29.6%, SCLC in 19.0%, NSCLC in 10.2% and others. Of the pts, 45.5% had a comorbid disease, 49.3% had weight loss (at least 5% of body weight), and 31.6% had a history of cancer in family. PET-CT was used in 83.3% of the pts for diagnosis of staging. Metastasis was detected in 54.2% of pts (43.9% bone, 23.1% brain, %20.2% liver, 17.3% surrenal metastasis). Treatment options were chemotherapy in 45.9%, chemo-radiotherapy in 28.2%, and surgery in 18.4% of the pts. Chemotherapy was mostly platin based doubles including etoposide (14.9%), paclitaxel (14.0%), gemcitabine (12.3%), docetaxol (4.3%), pemetrexed (2.2%), vinorelbin (4.9%), and others. The use of targeted therapies was detected in 1.1% of the pts. Palliative radiotherapy was given in 21.1% of the pts (8.5% brain, 7.2% bone, 6.7% thorax, and others). Interventional bronchoscopy or bronchial stenting was performed in 2.0% and pleurodesis in 1.8%. Of the pts, 10.5% reported the use of herbal medicine products. Most pts with lung cancer presented in advanced stages and only 18.4% had a chance for surgery. Conventional chemotherapy and radiotherapy was the most common therapeutic options but the use of targeted therapies and interventional procedures seems to be quite low.